Response to antiretroviral therapy in occult hepatitis B and HIV co-infection in West Africa.
Identifieur interne : 000507 ( Ncbi/Merge ); précédent : 000506; suivant : 000508Response to antiretroviral therapy in occult hepatitis B and HIV co-infection in West Africa.
Auteurs : David Chadwick [Royaume-Uni] ; Alastair Stanley ; Stephen Sarfo ; Lambert Appiah ; Michael Ankcorn ; Geraldine Foster ; Uli Schwab ; Richard Phillips ; Anna M. GerettiSource :
- AIDS (London, England) [ 1473-5571 ] ; 2013.
Descripteurs français
- KwdFr :
- Agents antiVIH (usage thérapeutique), Antigènes de surface du virus de l'hépatite B (sang), Charge virale (), Co-infection, Femelle, Ghana (épidémiologie), Humains, Hépatite B (immunologie), Hépatite B (traitement médicamenteux), Hépatite B (épidémiologie), Indice de masse corporelle, Infections à VIH (immunologie), Infections à VIH (traitement médicamenteux), Infections à VIH (épidémiologie), Inhibiteurs de la transcriptase inverse (usage thérapeutique), Lamivudine (usage thérapeutique), Mâle, Numération des lymphocytes CD4, Prévalence, Résultat thérapeutique, Évolution de la maladie.
- MESH :
- immunologie : Hépatite B, Infections à VIH.
- sang : Antigènes de surface du virus de l'hépatite B.
- traitement médicamenteux : Hépatite B, Infections à VIH.
- usage thérapeutique : Agents antiVIH, Inhibiteurs de la transcriptase inverse, Lamivudine.
- épidémiologie : Ghana, Hépatite B, Infections à VIH.
- Charge virale, Co-infection, Femelle, Humains, Indice de masse corporelle, Mâle, Numération des lymphocytes CD4, Prévalence, Résultat thérapeutique, Évolution de la maladie.
- Wicri :
- geographic : Ghana.
English descriptors
- KwdEn :
- Anti-HIV Agents (therapeutic use), Body Mass Index, CD4 Lymphocyte Count, Coinfection, Disease Progression, Female, Ghana (epidemiology), HIV Infections (drug therapy), HIV Infections (epidemiology), HIV Infections (immunology), Hepatitis B (drug therapy), Hepatitis B (epidemiology), Hepatitis B (immunology), Hepatitis B Surface Antigens (blood), Humans, Lamivudine (therapeutic use), Male, Prevalence, Reverse Transcriptase Inhibitors (therapeutic use), Treatment Outcome, Viral Load (drug effects).
- MESH :
- chemical , blood : Hepatitis B Surface Antigens.
- chemical , therapeutic use : Anti-HIV Agents, Lamivudine, Reverse Transcriptase Inhibitors.
- geographic , epidemiology : Ghana.
- drug effects : Viral Load.
- drug therapy : HIV Infections, Hepatitis B.
- epidemiology : HIV Infections, Hepatitis B.
- immunology : HIV Infections, Hepatitis B.
- Body Mass Index, CD4 Lymphocyte Count, Coinfection, Disease Progression, Female, Humans, Male, Prevalence, Treatment Outcome.
Abstract
This study evaluated the outcome of first-line antiretroviral therapy among 35 Ghanaians with occult HBV/HIV co-infection, comparing them over 2 years to 120 patients with HBsAg+ HBV/HIV co-infection and 230 patients without HBV co-infection. Increases in CD4 cell count and BMI were similar, whereas elevations of hepatic transaminases were more frequent in both the occult HBV and HBsAg+ patients. Occult HBV/HIV co-infection appears not to impact adversely on response to antiretroviral therapy in Ghana.
DOI: 10.1097/QAD.0b013e3283589879
PubMed: 22874516
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000256
- to stream PubMed, to step Curation: 000256
- to stream PubMed, to step Checkpoint: 000256
Links to Exploration step
pubmed:22874516Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Response to antiretroviral therapy in occult hepatitis B and HIV co-infection in West Africa.</title><author><name sortKey="Chadwick, David" sort="Chadwick, David" uniqKey="Chadwick D" first="David" last="Chadwick">David Chadwick</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Clinical Infection, The James Cook University Hospital, Middlesbrough, UK. davidr.chadwick@stees.nhs.uk</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Centre for Clinical Infection, The James Cook University Hospital, Middlesbrough</wicri:regionArea><wicri:noRegion>Middlesbrough</wicri:noRegion></affiliation></author><author><name sortKey="Stanley, Alastair" sort="Stanley, Alastair" uniqKey="Stanley A" first="Alastair" last="Stanley">Alastair Stanley</name></author><author><name sortKey="Sarfo, Stephen" sort="Sarfo, Stephen" uniqKey="Sarfo S" first="Stephen" last="Sarfo">Stephen Sarfo</name></author><author><name sortKey="Appiah, Lambert" sort="Appiah, Lambert" uniqKey="Appiah L" first="Lambert" last="Appiah">Lambert Appiah</name></author><author><name sortKey="Ankcorn, Michael" sort="Ankcorn, Michael" uniqKey="Ankcorn M" first="Michael" last="Ankcorn">Michael Ankcorn</name></author><author><name sortKey="Foster, Geraldine" sort="Foster, Geraldine" uniqKey="Foster G" first="Geraldine" last="Foster">Geraldine Foster</name></author><author><name sortKey="Schwab, Uli" sort="Schwab, Uli" uniqKey="Schwab U" first="Uli" last="Schwab">Uli Schwab</name></author><author><name sortKey="Phillips, Richard" sort="Phillips, Richard" uniqKey="Phillips R" first="Richard" last="Phillips">Richard Phillips</name></author><author><name sortKey="Geretti, Anna M" sort="Geretti, Anna M" uniqKey="Geretti A" first="Anna M" last="Geretti">Anna M. Geretti</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:22874516</idno><idno type="pmid">22874516</idno><idno type="doi">10.1097/QAD.0b013e3283589879</idno><idno type="wicri:Area/PubMed/Corpus">000256</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000256</idno><idno type="wicri:Area/PubMed/Curation">000256</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000256</idno><idno type="wicri:Area/PubMed/Checkpoint">000256</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000256</idno><idno type="wicri:Area/Ncbi/Merge">000507</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Response to antiretroviral therapy in occult hepatitis B and HIV co-infection in West Africa.</title><author><name sortKey="Chadwick, David" sort="Chadwick, David" uniqKey="Chadwick D" first="David" last="Chadwick">David Chadwick</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Clinical Infection, The James Cook University Hospital, Middlesbrough, UK. davidr.chadwick@stees.nhs.uk</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Centre for Clinical Infection, The James Cook University Hospital, Middlesbrough</wicri:regionArea><wicri:noRegion>Middlesbrough</wicri:noRegion></affiliation></author><author><name sortKey="Stanley, Alastair" sort="Stanley, Alastair" uniqKey="Stanley A" first="Alastair" last="Stanley">Alastair Stanley</name></author><author><name sortKey="Sarfo, Stephen" sort="Sarfo, Stephen" uniqKey="Sarfo S" first="Stephen" last="Sarfo">Stephen Sarfo</name></author><author><name sortKey="Appiah, Lambert" sort="Appiah, Lambert" uniqKey="Appiah L" first="Lambert" last="Appiah">Lambert Appiah</name></author><author><name sortKey="Ankcorn, Michael" sort="Ankcorn, Michael" uniqKey="Ankcorn M" first="Michael" last="Ankcorn">Michael Ankcorn</name></author><author><name sortKey="Foster, Geraldine" sort="Foster, Geraldine" uniqKey="Foster G" first="Geraldine" last="Foster">Geraldine Foster</name></author><author><name sortKey="Schwab, Uli" sort="Schwab, Uli" uniqKey="Schwab U" first="Uli" last="Schwab">Uli Schwab</name></author><author><name sortKey="Phillips, Richard" sort="Phillips, Richard" uniqKey="Phillips R" first="Richard" last="Phillips">Richard Phillips</name></author><author><name sortKey="Geretti, Anna M" sort="Geretti, Anna M" uniqKey="Geretti A" first="Anna M" last="Geretti">Anna M. Geretti</name></author></analytic><series><title level="j">AIDS (London, England)</title><idno type="eISSN">1473-5571</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-HIV Agents (therapeutic use)</term><term>Body Mass Index</term><term>CD4 Lymphocyte Count</term><term>Coinfection</term><term>Disease Progression</term><term>Female</term><term>Ghana (epidemiology)</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (epidemiology)</term><term>HIV Infections (immunology)</term><term>Hepatitis B (drug therapy)</term><term>Hepatitis B (epidemiology)</term><term>Hepatitis B (immunology)</term><term>Hepatitis B Surface Antigens (blood)</term><term>Humans</term><term>Lamivudine (therapeutic use)</term><term>Male</term><term>Prevalence</term><term>Reverse Transcriptase Inhibitors (therapeutic use)</term><term>Treatment Outcome</term><term>Viral Load (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Agents antiVIH (usage thérapeutique)</term><term>Antigènes de surface du virus de l'hépatite B (sang)</term><term>Charge virale ()</term><term>Co-infection</term><term>Femelle</term><term>Ghana (épidémiologie)</term><term>Humains</term><term>Hépatite B (immunologie)</term><term>Hépatite B (traitement médicamenteux)</term><term>Hépatite B (épidémiologie)</term><term>Indice de masse corporelle</term><term>Infections à VIH (immunologie)</term><term>Infections à VIH (traitement médicamenteux)</term><term>Infections à VIH (épidémiologie)</term><term>Inhibiteurs de la transcriptase inverse (usage thérapeutique)</term><term>Lamivudine (usage thérapeutique)</term><term>Mâle</term><term>Numération des lymphocytes CD4</term><term>Prévalence</term><term>Résultat thérapeutique</term><term>Évolution de la maladie</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Hepatitis B Surface Antigens</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-HIV Agents</term><term>Lamivudine</term><term>Reverse Transcriptase Inhibitors</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Ghana</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Viral Load</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term><term>Hepatitis B</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>HIV Infections</term><term>Hepatitis B</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Hépatite B</term><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>HIV Infections</term><term>Hepatitis B</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Antigènes de surface du virus de l'hépatite B</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hépatite B</term><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents antiVIH</term><term>Inhibiteurs de la transcriptase inverse</term><term>Lamivudine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Ghana</term><term>Hépatite B</term><term>Infections à VIH</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Body Mass Index</term><term>CD4 Lymphocyte Count</term><term>Coinfection</term><term>Disease Progression</term><term>Female</term><term>Humans</term><term>Male</term><term>Prevalence</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Charge virale</term><term>Co-infection</term><term>Femelle</term><term>Humains</term><term>Indice de masse corporelle</term><term>Mâle</term><term>Numération des lymphocytes CD4</term><term>Prévalence</term><term>Résultat thérapeutique</term><term>Évolution de la maladie</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Ghana</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This study evaluated the outcome of first-line antiretroviral therapy among 35 Ghanaians with occult HBV/HIV co-infection, comparing them over 2 years to 120 patients with HBsAg+ HBV/HIV co-infection and 230 patients without HBV co-infection. Increases in CD4 cell count and BMI were similar, whereas elevations of hepatic transaminases were more frequent in both the occult HBV and HBsAg+ patients. Occult HBV/HIV co-infection appears not to impact adversely on response to antiretroviral therapy in Ghana.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22874516</PMID><DateCreated><Year>2012</Year><Month>12</Month><Day>12</Day></DateCreated><DateCompleted><Year>2013</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-5571</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>Jan</Month><Day>02</Day></PubDate></JournalIssue><Title>AIDS (London, England)</Title><ISOAbbreviation>AIDS</ISOAbbreviation></Journal><ArticleTitle>Response to antiretroviral therapy in occult hepatitis B and HIV co-infection in West Africa.</ArticleTitle><Pagination><MedlinePgn>139-41</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/QAD.0b013e3283589879</ELocationID><Abstract><AbstractText>This study evaluated the outcome of first-line antiretroviral therapy among 35 Ghanaians with occult HBV/HIV co-infection, comparing them over 2 years to 120 patients with HBsAg+ HBV/HIV co-infection and 230 patients without HBV co-infection. Increases in CD4 cell count and BMI were similar, whereas elevations of hepatic transaminases were more frequent in both the occult HBV and HBsAg+ patients. Occult HBV/HIV co-infection appears not to impact adversely on response to antiretroviral therapy in Ghana.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chadwick</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Clinical Infection, The James Cook University Hospital, Middlesbrough, UK. davidr.chadwick@stees.nhs.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stanley</LastName><ForeName>Alastair</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sarfo</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Appiah</LastName><ForeName>Lambert</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Ankcorn</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Foster</LastName><ForeName>Geraldine</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Schwab</LastName><ForeName>Uli</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Phillips</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Geretti</LastName><ForeName>Anna M</ForeName><Initials>AM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MRC_MR/J01477X/1</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>AIDS</MedlineTA><NlmUniqueID>8710219</NlmUniqueID><ISSNLinking>0269-9370</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006514">Hepatitis B Surface Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018894">Reverse Transcriptase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>2T8Q726O95</RegistryNumber><NameOfSubstance UI="D019259">Lamivudine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="N">Body Mass Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018791" MajorTopicYN="N">CD4 Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060085" MajorTopicYN="N">Coinfection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005869" MajorTopicYN="N" Type="Geographic">Ghana</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006509" MajorTopicYN="N">Hepatitis B</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006514" MajorTopicYN="N">Hepatitis B Surface Antigens</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019259" MajorTopicYN="N">Lamivudine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018894" MajorTopicYN="N">Reverse Transcriptase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22874516</ArticleId><ArticleId IdType="doi">10.1097/QAD.0b013e3283589879</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Royaume-Uni</li></country></list><tree><noCountry><name sortKey="Ankcorn, Michael" sort="Ankcorn, Michael" uniqKey="Ankcorn M" first="Michael" last="Ankcorn">Michael Ankcorn</name><name sortKey="Appiah, Lambert" sort="Appiah, Lambert" uniqKey="Appiah L" first="Lambert" last="Appiah">Lambert Appiah</name><name sortKey="Foster, Geraldine" sort="Foster, Geraldine" uniqKey="Foster G" first="Geraldine" last="Foster">Geraldine Foster</name><name sortKey="Geretti, Anna M" sort="Geretti, Anna M" uniqKey="Geretti A" first="Anna M" last="Geretti">Anna M. Geretti</name><name sortKey="Phillips, Richard" sort="Phillips, Richard" uniqKey="Phillips R" first="Richard" last="Phillips">Richard Phillips</name><name sortKey="Sarfo, Stephen" sort="Sarfo, Stephen" uniqKey="Sarfo S" first="Stephen" last="Sarfo">Stephen Sarfo</name><name sortKey="Schwab, Uli" sort="Schwab, Uli" uniqKey="Schwab U" first="Uli" last="Schwab">Uli Schwab</name><name sortKey="Stanley, Alastair" sort="Stanley, Alastair" uniqKey="Stanley A" first="Alastair" last="Stanley">Alastair Stanley</name></noCountry><country name="Royaume-Uni"><noRegion><name sortKey="Chadwick, David" sort="Chadwick, David" uniqKey="Chadwick D" first="David" last="Chadwick">David Chadwick</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000507 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000507 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:22874516
|texte= Response to antiretroviral therapy in occult hepatitis B and HIV co-infection in West Africa.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:22874516" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |